+86-28-82633987
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
70.6700
5.3445
5.3077
.0115
2.2983
19.4403
Low
93.9835
2.7547
No
No
Yes
No
Yes
Yes
0.0
No
Yes
Yes
No
8-Geranyl daidzein is an isoflavone compound derived from natural plants and belongs to the category of daidzein derivatives. As a functional natural product, 8-geranilagin-based daidzein has attracted widespread attention in recent years in pharmacology and natural product drug development due to its unique structural modification and bioactivity. Its main biological function involves estrogen regulation, allowing it to act on various hormone receptors and related enzyme targets, demonstrating potential therapeutic advantages, especially with significant research value in hormone-related diseases such as breast cancer, menopausal syndrome, and osteoporosis.
This paper aims to systematically review the chemical structure and physicochemical properties of 8-geranial-based daidzeigone, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation, and pharmacokinetic characteristics, and finally discuss its clinical application prospects and development trends, providing a theoretical foundation and reference for subsequent research and drug development.
The molecular formula of 8-gerani-based daidzeigin is C_25H_30O_4, with a molecular weight of 390.4790. Its structure is based on the daidzein core backbone, and by introducing geranyl side chains at position 8, it forms derivatives with strong hydrophobicity. This structural modification not only increases the molecule's lipid solubility (LogP value 5.3445), but may also affect its binding affinity to biological targets and cell membrane permeability.
In terms of physicochemical properties, the topological polarity surface area (TPSA) of 8-geranial-based daidzenet is 70.67 Ų, indicating moderate polarity that facilitates interaction with protein targets. Low water solubility (about 0.0115 mg/mL) suggests limited solubility in the aqueous phase, which may affect its bioavailability. The blood-brain barrier has a low penetration capacity, suggesting limited distribution in the central nervous system. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. Ames-induced mutagenesis test results were zero, indicating a low genotoxicity risk.
In summary, the structural characteristics and physicochemical properties of 8-gerania-based daidzeigin provide a solid foundation for its use as a drug molecule, but its high hydrophobicity and low water solubility also suggest the need for optimized bioavailability through pharmacological methods.
8-Gerani-based daidzein is mainly found in certain legume plants, especially soybeans (Glycine max) and related varieties. As a derivative of daidzein savingin, it is usually generated in plants via isoflavone biosynthesis pathways, and then, under specific conditions, enzymatic reactions introduce the geraisan base-based side chain.
Traditional extraction methods mostly use organic solvent extraction techniques, such as methanol, ethanol, or ethyl acetate, combined with ultrasound-assisted extraction or reflux extraction to improve extraction efficiency. Subsequently, separation and purification are carried out through liquid-liquid partitioning and column chromatography (silica gel column, C18 reversed phase column). High-performance liquid chromatography (HPLC) and mass spectrometry techniques are widely used for qualitative and quantitative analysis.
In recent years, green extraction technologies such as supercritical CO_2 extraction and microwave-assisted extraction have gradually been applied to the extraction of this compound, aiming to improve extraction efficiency, reduce solvent usage, and reduce environmental pollution. In addition, the development of biosynthesis and chemical synthesis routes also provides new avenues for obtaining high-purity 8-gerania-based daidzeigone.
Pharmacological activity studies of 8-gerani-based daidzeigin mainly focus on its regulatory effects on estrogen-related diseases. As a natural isoflavone derivative, its structure shares certain similarities with estrogen in the human body, allowing it to bind to estrogen receptors (ER) and exert selective regulatory effects.
Multiple in vitro and in vivo studies have shown that 8-geranilaginyl daidzein can regulate the expression and activity of ESR1 (estrogen receptor α) and ESR2 (estrogen receptor β), exhibiting bidirectional estrogen-like or anti-estrogen regulatory properties. By modulating the ER signaling pathway, 8-gerania-based daidzein has shown potential therapeutic effects in breast cancer cell proliferation, bone metabolism regulation, and neuroprotection.
Additionally, this compound affects SHBG (sex hormone-binding globulin) levels, regulating free hormone concentrations in the body and thereby influencing hormone bioactivity. Inhibition of CYP19A1 (aromatase) may reduce estrogen synthesis, showing potential for anti-hormone-dependent tumors.
8-Gerani-based daidzeigone also acts on various hormone receptors and related proteins, including AR (androgen receptor), PGR (progesterone receptor), FSHR (follicle-stimulating hormone receptor), and LHB (luteinizing hormone β subunit), demonstrating its multi-target role in endocrine regulation. This multi-target regulation provides a theoretical basis for treating various hormone imbalance-related diseases (such as polycystic ovary syndrome, menopausal symptoms, prostate diseases, etc.).
In addition to hormonal regulation, 8-gerania-based daidzeigin also exhibits significant antioxidant and anti-inflammatory activities. It can eliminate free radicals, reduce oxidative stress levels, inhibit the expression of inflammatory factors, and lessen tissue damage. These effects support its potential applications in cardiovascular diseases, neurodegenerative diseases, and metabolic syndromes.
The mechanism of action of 8-geranial-based daidzein mainly relies on interactions with various hormone receptors and related enzyme targets.
Through molecular docking and cell experiments, it was found that 8-geranilagin-based daidzeigine can selectively bind to ESR1 and ESR2, regulate receptor conformations, and activate or inhibit their downstream signaling pathways. Its high affinity for ESR2 may lead to enhanced anti-proliferative and anti-inflammatory signaling mediated by ERβ.
Aromatase (CYP19A1) is a key enzyme for estrogen biosynthesis. 8-geranial-based daidzein competitively inhibits the activity of this enzyme, reducing the synthesis of estradiol and estradiol, thereby lowering estrogen levels in the body and exerting therapeutic effects against hormone-dependent tumors.
This compound regulates receptors such as AR, PGR, FHR, and LHB, involving receptor expression regulation and activation or inhibition of signal transduction pathways, affecting hormone synthesis, release, and target cell responses, demonstrating its complex endocrine regulatory functions.
8-Gerani-based daidzein enhances antioxidant enzyme expression by activating the Nrf2/ARE signaling pathway, inhibits the NF-κB pathway, reduces inflammatory factor release, and alleviates cellular oxidative damage and inflammatory responses.
According to existing data, the LogP value of 8-gerani-based daidzein is 5.3445, making it a highly lipid-soluble compound, indicating good cell membrane permeability, but its low water solubility (0.0115 mg/mL) may limit its oral absorption and bioavailability. TPSA is 70.67 Ų, meeting the Lipinski rule requirements for polar surface area, which benefits the biological activity of the drug.
The low penetration capacity of the blood-brain barrier suggests its limited distribution in the central nervous system, which may reduce CNS-related side effects. hERG channel inhibition was negative, reducing the risk of cardiotoxicity. The Ames test was negative, indicating a low risk of genotoxicity.
Currently, systematic pharmacokinetic research on 8-gerani-based daidzeigin is relatively limited. Preliminary in vivo experiments show that the compound is absorbed slowly after oral administration, has a moderate plasma half-life, and is mainly metabolized by the liver; the metabolites still require systematic identification. Its high lipid solubility may lead to a wide tissue distribution, but its low water solubility limits its solubility and transport in the blood.
Future research on in vivo pharmacokinetics and toxicology is needed to clarify its absorption, distribution, metabolism, and excretion (ADME) characteristics, providing a basis for clinical development.
8-Geranial-based daidzein demonstrates broad clinical application potential due to its multi-target regulation of hormone receptors and related enzyme functions. Its application in hormone-related diseases is particularly prominent, including:
However, current research on its clinical safety, effective dosage, and long-term application effects is still insufficient, and systematic preclinical and clinical trials are needed. In addition, its low water solubility and bioavailability issues need to be addressed through modern pharmaceutical technologies such as nanocarriers and liposomes.
Future research should focus on:
8-Gerami-based daidzeigone, as a natural isoflavone derivative, demonstrates significant pharmacological value in the prevention and treatment of hormone-related diseases due to its unique chemical structure and multi-target regulatory effects. Its excellent safety indicators and multiple biological activities provide a solid foundation for the development of novel natural medicines. Although challenges such as water solubility and bioavailability still remain, with advances in pharmaceutics and molecular biology technologies, 8-gerania-based daidzein is expected to become an important candidate molecule for future natural product drug development.
Future research should strengthen the integration of basic and applied applications, promote clinical translation, fully realize its potential in the field of natural product pharmacology, and contribute new therapeutic strategies to human health.
Shenshuai
Wenjing
Hedandan
